Traders Purchase a Large Volume of SIGA Technologies Call ... - Best Stocks

On Wednesday, there was an unexpectedly high volume of activity involving trading options in relation to SIGA Technologies, Inc. (NASDAQ: SIGA). The company’s stockholders collectively purchased 1,200 call options for the business. This constitutes a 1,438% increase in activity when weighed against the typical volume of 78 call options traded.

The NASDAQ SIGA stock was first offered for trading on Thursday for $7.29. Over the previous 52 weeks, the price of SIGA Technologies ranged from its all-time low of $5.84 to its all-time high of $26.99. The simple moving average price of the company’s shares over the past 50 days is $8.65, while the average price over the last 200 days is $12.37. The stock’s price-to-earnings ratio is 5.03, and its beta value is 0.72. The company’s total value, as measured by its market capitalization, is $532.34 million.
Hedge funds have been very active in stock transactions involving the company, buying and selling shares. SummerHaven Investment Management LLC increased its stake in SIGA Technologies during the third quarter by purchasing additional shares for a total cost of approximately $606,000. Timelo Investment Management Inc. purchased an additional interest in SIGA Technologies for approximately 579 000 dollars during the second quarter. A total investment of $126,000 was made in SIGA Technologies by the Bank of Nova Scotia during the second quarter. Kempen Capital Management N.V. increased the proportion of SIGA Technologies owned by 19.5% during the year’s first three months. After making additional purchases totaling 224,423 shares during the most recent fiscal quarter, Kempen Capital Management N.V. now has 1,376,982 shares of the company’s stock. There is a value of $9,763,000 attached to these shares.
Last but not least, during the first quarter, Amalgamated Bank invested approximately $56,000 in SIGA Technologies to fill a newly created position. This investment should not be considered the least important. The company’s stock is held collectively by hedge funds and other types of institutional investors to the extent of 39.44%.
SIGA Technologies, Inc., a pharmaceutical company based in the United States currently transitioning to the commercial stage of development, places a primary emphasis on the health security and infectious disease industries as its primary areas of concentration. The Variola virus brings on the human disease known as smallpox. The TPOXX drug is an oral antiviral formulation that is used to treat patients who have been diagnosed with this condition. This treatment is the one that the company is most proud of producing. SIGA Technologies, Inc. and Cipla Therapeutics have formed a strategic partnership to speed up the production of antibacterial drugs, primarily to protect against biothreats. The goal of the partnership is to expedite the production of antibacterial drugs.

Adblock test (Why?)